PCDH19 clustering epilepsy
An X-linked epilepsy that mainly affects girls in fever-triggered clusters — with a neurosteroid (ganaxolone) showing targeted benefit in trials.
PCDH19 clustering epilepsy is a genetic epilepsy caused by variants in the PCDH19 gene. It has an unusual inheritance pattern that mainly affects girls, with seizures that come in clusters — often triggered by fever — typically beginning in infancy. Many children also have intellectual disability, autism or behavioural difficulties. The epilepsy can be hard to treat, but research into the underlying biology has led to a targeted neurosteroid therapy, ganaxolone, with promising trial results.
At a glance
- Gene
- PCDH19 (X-linked, unusual inheritance)
- Who
- Mainly affects girls; transmitting males usually unaffected
- Hallmark
- Fever-triggered seizure clusters from infancy
- Often with
- Intellectual disability, autism, behavioural difficulties
- Targeted therapy
- Ganaxolone (neurosteroid) studied in trials
What it is
PCDH19 clustering epilepsy is distinctive in two ways. First, its inheritance is unusual: although the gene is on the X chromosome, it is heterozygous females (girls with one altered and one normal copy) who are typically affected, while males who carry the change are usually unaffected — thought to be due to a mechanism called cellular interference. Second, the seizures characteristically occur in clusters, often set off by fever, beginning in infancy or early childhood.
Many girls also have intellectual disability, autism spectrum features or behavioural and psychiatric difficulties, which can become as important as the seizures over time.
Diagnosis and treatment
Diagnosis is by genetic testing, in a child with the typical clustering, fever-sensitive seizures. The seizures can be difficult to control; medicines such as clobazam, bromide and corticosteroids are used, often with extra cover during illness and fever.
Research suggests that PCDH19 disrupts neurosteroid (allopregnanolone) signalling, which provided a rationale for ganaxolone — a synthetic neurosteroid. In a randomized placebo-controlled trial (VIOLET), ganaxolone reduced seizures by more than 60% versus about 24% with placebo, and was generally well tolerated (drowsiness being the most common effect). Ganaxolone is already approved for another genetic epilepsy (CDKL5 deficiency disorder).
PCDH19 is an example of biology pointing to a targeted treatment: understanding its effect on neurosteroids led to trials of ganaxolone. Whether and when to use it is a decision for the treating specialist.
How an educational review can help
An educational review can explain the unusual inheritance, the genetic result and the cluster pattern, and put treatment options — including newer targeted therapy — in context, helping you prepare questions for your treating team. It is educational and does not replace your clinician's care.
Selected sources
- Phase 2, randomized, placebo-controlled study of oral ganaxolone in PCDH19-clustering epilepsy (VIOLET).
- Reviews of PCDH19-related epilepsy: clinical features, inheritance and management.
Last reviewed: 2026-05-22
Related treatments
Have a report you want explained?
Share your child's records and our specialists will prepare a written educational review.
Start a ReviewZatay Medical provides independent educational reviews only. Our reports are not a diagnosis, treatment, or prescription, and do not replace care from your treating physician.